samedan logo
 
 
 
spacer
home > pmps > summer 2019 > accuracy in patch pump therapy
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Accuracy in Patch Pump Therapy

Patch pump therapy is a convenient method of drug administration. The devices can be worn directly on the body, no tubing has to be attached, and the cannula or needle is inserted automatically. They are often equipped with programmable delivery patterns, which allow high flexibility and a rational adjustment to the patientís needs. In turn, the patch pumps must fulfil the highest criteria in dosage accuracy and safety. The fluidic path through the whole device, including body resistance at the injection site combined with the physical properties of the drug, define the pressure loss that the pump needs to overcome. Since smaller needles are more comfortable and, therefore, preferred, they often represent the bottleneck of the system.

Viscosity Range of Suitable Medication

Many common drugs for patch pump therapy are aqueous solutions in the range of 1cP to 30cP. Fluids with higher agent concentration or larger molecules may reach up to 50cP or even higher. This often requires large needle diameters or significantly lower flow rates.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Michael Girschweiler has worked at Sensile Medical since 2017. Michael is Technical Project Leader in the field of micropump development and an expert in the companyís pump core technology. He has a Bachelorís degree in Mechanical Engineering and worked as Research Assistant at the Institute of Thermal and Fluid Engineering at the University of Northwestern Switzerland, mainly in FEM and CFD simulations of thermomechanical projects.
spacer
Michael Girschweiler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement